Description: Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women's health, central nervous system, oncology, immunology, genomics, metabolic disorders, dermatology, urology, pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies, as well as engages in the bio clinical research activities. It operates through network consists of labs, LupiMitra collection centers, and pick-up points. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.
Home Page: www.lupin.com
Kalpataru Inspire
Mumbai,
400055
India
Phone:
91 22 6640 2323
Officers
| Name | Title |
|---|---|
| Ms. Vinita D. Gupta | CEO & Executive Director |
| Mr. Ramesh Swaminathan | Executive Director, Global CFO, CRO & Head of API Plus SBU |
| Mr. Nilesh Deshbandhu Gupta | MD & Executive Director |
| Mr. Christoph Funke | Chief Technical Operations Officer |
| Mr. Sreeji Gopinathan | Chief Information Officer |
| Dr. Shahin Fesharaki | President -Global Chief Scientific Officer |
| Mr. Ravi Agrawal | Sr. Vice President of Investor Relations and M&A |
| Dr. Sofia Mumtaz | President of Legal and Compliance of Australia, Japan & Canada Business |
| Mr. Amit Kumar Gupta | Company Secretary & Compliance Officer |
| Ms. Rajalakshmi Azariah | Vice President & Global Head of Corporate Communications |
Exchange: NSE
Country: IN : India
Currency: Indian Rupee (INR)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 18.0505 |
|---|---|
| Trailing PE: | 37.1763 |
| Price-to-Book MRQ: | 6.2225 |
| Price-to-Sales TTM: | 4.5298 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 19210 |